Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Regneneron | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Regneneron

EYLEA sales up 39% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regneneron

4Q Revenues: $802.3 million (+31%)

4Q Earnings: $110.2 million (+14%)

FY Revenues: $2.8 billion (+34%)

FY Earnings: $348.1 million (-18%)

Comments: EYLEA Injection sales increased 39% to $815 million in the quarter, with sales of $518 million in the U.S. and $297 million in rest of world. Bayer HealthCare commercializes EYLEA outside the U.S., of which Regeneron recognized $88 million after development expenses. In October 2014, the FDA approved EYLEA for the treatment of macular edema following retinal vein occlusion (RVO), which includes macular edema following branch retinal vein occlusion (BRVO).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters